3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
61
Observational
5
Expanded_access
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Interventions
veliparib
2
tucatinib
2
leronlimab
2
abemaciclib
2
Trastuzumab
2
Capecitabine
2
Alpelisib
2
zenocutuzumab
1
selpercatinib
1
sacituzumab govitecan
1
ribociclib
1
pertuzumab
1
pegilodecakin
1
palbociclib
1
margetuximab
1
iniparib
1
glembatumumab vedotin
1
gedatolisib
1
eribulin
1
Vinorelbine
1
Proton Pump Inhibitors
1
Letrozole
1
Lapatinib
1
Hydrocortisone
1
Everolimus
1
Cisplatin
1
Ado-Trastuzumab Emtansine
1
AM0010
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
sacituzumab govitecan
×
Breast
×
Clear all
NCT04320693
2021-08-19
Expanded Access for IMMU-132
Gilead Sciences
Approved for marketing